Additional Collaboration Clause Samples

Additional Collaboration. Within [***] after the Effective Date, the Parties will discuss the [***].
View SourceView Similar (2)
Additional Collaboration. Novatel Wireless and Intel will engage in the following technical collaboration: a) Novatel Wireless, in consultation with and support from Intel, will provide all personnel, resources, and IP to complete the work described in the statement of work attached in Exhibit J-1, also referred to as Phase 1b. The parties recognize that they have not set forth in full detail all technical aspects of the statement of work attached in Exhibit J-1. Upon execution of this agreement, the parties will complete this statement in reasonable detail. If the parties are unable for any reason to agree on such details within sixty (60) calendar days following the effective date, Novatel Wireless will in good faith perform the work as presently described with a goal of making Novatel Wireless technology work as well on platforms targeted in the statement of work attached as Exhibit J-1 as on any other silicon, board or system architecture. b) Novatel Wireless presently intends to perform the work described in the statements of work set forth in Exhibits J-2 also referred to as Phase 2. The parties recognized that they have reached full agreement upon the advisability or the scope of this work. Upon execution of this agreement, Novatel Wireless will in good faith agree with Intel on this scope of this work. If the parties are unable for any reason to agree on such details within ninety (90) calendar days following the effective date, Novatel Wireless will in good faith perform the work as presently described with a goal of making Novatel Wireless technology for Software Reconfigurable Radios work on Intel Silicon. c) Assuming the success of Phase 2 technology development (as mutually defined and agreed to by both companies), the productization of such technology will be undertaken as set forth in Exhibit J-3 also referred to as Phase 2b. The parties recognized that they have reached full agreement upon the advisability or the scope of this work - given that the Phase 2 technology achieves its performance and cost targets. Upon execution of this agreement, Novatel Wireless will in good faith agree with Intel on the next level of details for this phase. If the parties are unable for any reason to agree on such details within 365 calendar days following the effective date, the high level terms set forth in the current exhibit will continue to remain in effect - unless mutually agreed to in writing between the two companies.
View SourceView Similar (2)
Additional Collaboration. The Parties shall exercise good-faith negotiations to enter into a separate collaboration aimed at the further development and commercialization of one or more therapeutics encompassing or employing an siRNA that is deliverable to the posterior pole of the eye which may be administered by systemic application for pharmaceutical use in humans (the “Systemic siRNA”). The financial terms of the Systemic siRNA collaboration shall be consistent with and substantially similar to the provisions of Sections 7.1, 7.3, 7.4, 7.5 and 7.6(a) of this Agreement, after taking into account and considering the relevant market for the Systemic siRNA and its expected commercial success.
View Source
Additional Collaboration. Party shall promptly provide to the other Party all data, materials and other information, and shall promptly take all such other actions, as may be reasonably requested by the other Party from time to time in order to perform its obligations hereunder and comply with all Laws applicable to the matters addressed in this Agreement. ARTICLE IIIEach Party shall cooperate with the other Party’s reasonable requests in responding to or resolving any complaint, investigation, inquiry or review initiated by a governmental agency, or otherwise relating to the Product or the services provided by either Party as described in this Agreement. Each Party shall cooperate with the reasonable request of any insurance company providing protection to either Party in connection with the foregoing.
View Source
Additional Collaboration. The parties anticipate that there may be additional opportunities for collaboration beyond what is described in this Agreement, and which may be generally expected of two public agencies operating within the same geographic area. It is not the purpose of this Agreement to modify or to formalize interactions that are within the normal course and scope of business between the two agencies or collaboration which may typically occur without an interlocal agreement in place. Such collaboration, which is not governed by this Agreement, may include but is not limited to, authoring letters of support for funding, participating in meetings with elected and agency officials, traveling to advocate for the parties in Washington DC or Olympia, and more.
View Source
Additional Collaboration. Upon execution of this MOU, individual institutions of NSHE may separately collaborate with the Secretary of Education in Tamaulipas, as well as Tamaulipas colleges and universities, to further develop and implement institution-specific programs and enter into agreements consistent with the intent, scope, and terms of this MOU.
View Source
Additional Collaboration. If Producer wishes to terminate any Author, such Author shall retain any and all amounts paid, or due and payable, by Producer to such Author hereunder at the time of such termination. Notwithstanding anything to the contrary herein, each Author acknowledges that the Film is an established story, and that, inevitably, different individuals approaching the material contained in the Film may develop such material in ways that are similar, and even in some cases identical, to such Author’s development of material hereunder. Such Author further acknowledges and agrees that Producer and Owner are entitled to discuss the Film with third parties and obtain third party ideas and suggestions for developing material related thereto, and if Producer or Owner ultimately uses material that is the same as or similar to material which such Author creates, such Author shall not be entitled to any compensation or credit except in the limited situation in which the original material created by such Author hereunder rises to the level of being separately protectable under the United States Copyright Act of 1976 (as amended), taking into account material owned by the Owner (including, without limitation, the Film), material provided to such Author by other authors of or contributions to the Play, material provided to such Author by Producer, material in the public domain, scènes à faire and similar doctrines, and any other defense that would be available in a copyright infringement litigation. If such Author alleges that any such separately protectable material has been used and Producer agrees with such allegation, Producer and such Author shall negotiate in good faith to determine an appropriate payment and attribution, but in the event of a disagreement either as to liability or compensation, the arbitration provisions of paragraph 19 below shall apply and, without limiting the generality of the foregoing or the other provisions of paragraph 19 below, such Author, and anyone claiming by, through or under such Author, shall not be entitled to equitable relief, whether injunctive or otherwise, in connection with the use of any such separately protectable materials. In any event, Producer shall be entitled to continue with the development of the Play during negotiations and/or the pendency of any dispute with such Author being replaced.
View Source

Related to Additional Collaboration

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Scope of Collaboration As part of the collaboration, the Controllers will act as Joint Controller. The roles of the Controller and the associated tasks are specified in more detail in Appendix 1. If one party is solely responsible for a data processing operation, this party will implement all relevant data protection provisions on its own responsibility. However, such data processing procedures are not subject to this Agreement. Joint data processing and the type of Personal Data collected and processed within the framework of collaboration are specified in Appendix 1.

  • Collaboration activities 4.1 The Collaboration Suppliers will perform the Collaboration Activities and all other obligations of this Agreement in accordance with the Detailed Collaboration Plan. 4.2 The Collaboration Suppliers will provide all additional cooperation and assistance as is reasonably required by the Buyer to ensure the continuous delivery of the services under the Call-Off Contract. 4.3 The Collaboration Suppliers will ensure that their respective subcontractors provide all cooperation and assistance as set out in the Detailed Collaboration Plan.

  • Additional Collateral (a) With respect to any Capital Stock of any newly created or acquired Subsidiary or any newly issued Capital Stock of any existing Subsidiary acquired after the Original Closing Date by the Borrower or any of its Subsidiaries that is intended to be subject to the Lien created by any of the Pledge Agreements but which is not so subject, promptly (and in any event within 30 days after the acquisition thereof): (i) execute and deliver to the Administrative Agent such amendments to the relevant Pledge Agreements or such other documents as the Administrative Agent shall deem necessary or advisable to grant to the Administrative Agent, for the benefit of the Lenders, a Lien on such Capital Stock, (ii) take all actions necessary or advisable to cause such Lien to be duly perfected in accordance with all applicable Requirements of Law, including delivering all such original certificates evidencing such Capital Stock to the Administrative Agent together with undated stock powers executed in blank therefor, and (iii) if requested by the Administrative Agent or the Required Lenders, deliver to the Administrative Agent legal opinions relating to the matters described in clauses (i) and (ii) immediately preceding, which opinions shall be in form and substance, and from counsel, reasonably satisfactory to the Administrative Agent. Notwithstanding the foregoing, the Borrower shall not be required to grant to the Administrative Agent a Lien upon the Capital Stock of any Immaterial Subsidiary. (b) With respect to any Person that, subsequent to the Original Closing Date, becomes a direct or indirect Subsidiary of the Borrower, promptly (and in any event within 30 days after such Person becomes a Subsidiary): (i) cause such new Subsidiary to become a party to the Subsidiary Pledge Agreement and the Subsidiary Guarantee and (ii) if requested by the Administrative Agent or the Required Lenders, deliver to the Administrative Agent legal opinions relating to the matters described in clause (i) immediately preceding, which opinions shall be in form and substance, and from counsel, reasonably satisfactory to the Administrative Agent. Notwithstanding the foregoing, no Immaterial Subsidiary or Foreign Subsidiary of the Borrower shall be required to execute a Subsidiary Guarantee or Subsidiary Pledge Agreement, and no more than 65% of the Capital Stock of or equity interests in any Foreign Subsidiary of the Borrower or any of its Subsidiaries if more than 65% of the assets of such Subsidiary are securities of foreign companies (such determination to be made on the basis of fair market value), shall be required to be pledged hereunder.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).